192 related articles for article (PubMed ID: 8485612)
21. An estradiol matrix transdermal system for the prevention of postmenopausal bone loss.
McKeever C; McIlwain H; Greenwald M; Gupta N; Jayawardene S; Huels G; Roberts M
Clin Ther; 2000 Jul; 22(7):845-57. PubMed ID: 10945511
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial.
Bachmann G; Lobo RA; Gut R; Nachtigall L; Notelovitz M
Obstet Gynecol; 2008 Jan; 111(1):67-76. PubMed ID: 18165394
[TBL] [Abstract][Full Text] [Related]
23. [Hormone replacement therapy with a transdermal estradiol gel and oral micronized progesterone. Effect on menopausal symptoms and lipid metabolism].
Giuliani A; Concin H; Wieser F; Boritsch J; Wilfert H; Gruber D; Urdl W
Wien Klin Wochenschr; 2000 Jul; 112(14):629-33. PubMed ID: 11008325
[TBL] [Abstract][Full Text] [Related]
24. [Transdermal estradiol--the possibility for replacement therapy in the postmenopause].
Rachev E
Akush Ginekol (Sofiia); 1994; 33(3):45-7. PubMed ID: 7793531
[TBL] [Abstract][Full Text] [Related]
25. Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial.
Valiati B; Capp E; Edelweiss MI; de Freitas FM; Wender MC
Maturitas; 2009 Jan; 62(1):81-4. PubMed ID: 19097715
[TBL] [Abstract][Full Text] [Related]
26. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch 40 and Estrapatch 60) with a twice week system.
Raynaud JP; Lévrier M; Calaf J; Laur C; Pélissier C
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):309-18. PubMed ID: 15860275
[TBL] [Abstract][Full Text] [Related]
28. [Transdermal administration of estrogens in women with the postcastration and climacteric syndromes].
Rotta L; Matĕchová E
Cesk Gynekol; 1992 Sep; 57(7):336-40. PubMed ID: 1394497
[TBL] [Abstract][Full Text] [Related]
29. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K
Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
[TBL] [Abstract][Full Text] [Related]
31. Pulsed estrogen therapy: relieving climacteric symptoms, preventing postmenopausal bone loss.
Palacios S
Climacteric; 2002 Jun; 5 Suppl 2():32-9. PubMed ID: 12482109
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation of the climacteric symptomatology modifications and clinical-instrumental parameters in women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and in surgical menopause treated with estrogen replacement therapy. Part I].
Savoca S; D'Agosta S; Lombardo G
Minerva Ginecol; 2007 Jun; 59(3):205-14. PubMed ID: 17576399
[TBL] [Abstract][Full Text] [Related]
33. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial.
Simon JA; Bouchard C; Waldbaum A; Utian W; Zborowski J; Snabes MC
Obstet Gynecol; 2007 Mar; 109(3):588-96. PubMed ID: 17329509
[TBL] [Abstract][Full Text] [Related]
34. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women.
Archer DF;
Menopause; 2003; 10(6):516-21. PubMed ID: 14627859
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study.
Lee BS; Kang BM; Yoon BK; Choi H; Park HM; Kim JG
Maturitas; 2007 Aug; 57(4):361-9. PubMed ID: 17467203
[TBL] [Abstract][Full Text] [Related]
36. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
37. Safety and tolerability of pulsed estrogen therapy: key factors for an improved compliance.
Mattsson LA
Climacteric; 2002 Jun; 5 Suppl 2():40-5. PubMed ID: 12482110
[TBL] [Abstract][Full Text] [Related]
38. Effects of postmenopausal hormone replacement therapy on body fat composition.
Yüksel H; Odabasi AR; Demircan S; Köseoğlu K; Kizilkaya K; Onur E
Gynecol Endocrinol; 2007 Feb; 23(2):99-104. PubMed ID: 17454160
[TBL] [Abstract][Full Text] [Related]
39. [Bioavailability of 17 beta-estradiol after transdermal administration--dependence on the patch system].
Schmolling J; Kusche J; van der Ven H; Schander K
Zentralbl Gynakol; 1998; 120(3):121-5. PubMed ID: 9556902
[TBL] [Abstract][Full Text] [Related]
40. Two routes of hormonal replacement therapy in symptomatic menopausal women after kidney transplantation.
Pietrzak B; Wielgos M; Kaminski P; Bobrowska K
Neuro Endocrinol Lett; 2006 Jun; 27(3):387-91. PubMed ID: 16816826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
